In vivo Tau pathology in PSP and CBD

• Research type

  Research Study

• Full title

  An 18F-T807 PET study to evaluate in vivo Tau pathology in Progressive Supranuclear Palsy and Corticobasal Degeneration.

• IRAS ID

  155665

• Contact name

  Marios Politis

• Contact email

  marios.politis@sitilop.com

• Sponsor organisation

  King's College London

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and Frontotemporal degeneration (FTD) are rare diseases associated with an over-production of a protein called tau in certain areas of the brain. In these diseases, tau forms into clumps – or neurofibrillary tangles – which are believed to damage nerve cells. Currently, no treatments for these diseases are available. The prevention of tau aggregation is the focus of attempts to develop mechanism-based treatments for tauopathies. We have now the possibility to assess in vivo tau aggregates using positron emission tomography (PET) and 18F-T807. In this study, we aim to investigate for the first time in vivo tau pathology in: (a) PSP as a model of pure tauopathy (b) CBD a models of mixed tauopathy where in some subtypes, other pathologies including amyloid are expected.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  15/LO/0624

• Date of REC Opinion

  28 Apr 2015

• REC opinion

  Further Information Favourable Opinion